CSTL Form 4: CEO Derek Maetzold sells 1,339 shares at $22.44
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences (CSTL) CEO and President Derek Maetzold reported an open‑market sale of common stock. On 10/20/2025, he sold 1,339 shares at a weighted‑average price of $22.44, marked with transaction code S and made pursuant to a Rule 10b5‑1 plan adopted on May 8, 2025.
Following the transaction, his direct beneficial ownership stands at 62,988 shares. He also reports indirect holdings through various trusts, including 85,959 shares by DJM Grantor Retained Annuity Trust No. 5 and 52,923 shares by The Maetzold Descendants 2020 Trust. The sale price reflects multiple trades executed between $22.290 and $22.615, with the weighted‑average disclosed.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,339 shares ($30,047)
Net Sell
10 txns
Insider
MAETZOLD DEREK J
Role
Pres. & Chief Exec. Officer
Sold
1,339 shs ($30K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,339 | $22.44 | $30K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 62,988 shares (Direct);
Common Stock — 52,923 shares (Indirect, By The Maetzold Descendants 2020 Trust)
Footnotes (1)
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. This transaction was executed in multiple trades at prices ranging from $22.290 to $22.615, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
FAQ
What did CSTL’s CEO report on Form 4?
He reported selling 1,339 shares of Castle Biosciences common stock on 10/20/2025.
Was the sale under a Rule 10b5-1 plan?
Yes. The transactions were made pursuant to a Rule 10b5‑1 plan adopted on May 8, 2025.
Does the CEO have additional indirect CSTL holdings?
Yes, through multiple trusts, including 85,959 shares (DJM GRAT No. 5) and 52,923 shares (Maetzold Descendants 2020 Trust).
What transaction code was used?
Transaction code S indicates an open‑market sale of common stock.